Vertex Reports Second-Quarter 2017 Financial Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/21/2026
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
- Paramount, Warner Bros jump on report of settlement progress in merger fight
- Investors may be underpricing how far rate hikes could go, Deutsche says
- Far-left party wins Berlin election, pledging to nationalise housing
- Cybercrime feud erupts on dark web as notorious group claims hijack of rival's website
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- Oil price dips to $100 on hopes of US-Iran diplomacy, partial recovery in Saudi exports
Vertex Pharma (VRTX) Tops Q2 EPS by 4c
July 26, 2017 4:02 PM EDTVertex Pharma (NASDAQ: VRTX) reported Q2 EPS of $0.39, $0.04 better than the analyst estimate of $0.35. Revenue for the quarter came in at $514 million versus the consensus estimate of $487.49 million.
Vertex reiterates 2017 guidance for ORKAMBI and KALYDECO product revenues; updates guidancefor... More
